Prova Education

Combination Drug Treatment Reduces Agitation in Patients with Alzheimer's Disease

Combination Drug Treatment Reduces Agitation in Patients with Alzheimer's Disease
RestartResume
    [Read the Article] Agitation is common in patients with dementia and can contribute to distress for patients and caregivers and an increased risk ...
    • Overview

      [Read the Article]

      Agitation is common in patients with dementia and can contribute to distress for patients and caregivers and an increased risk of institutionalization. Nonpharmacological interventions are recommended as first-line therapy, but many patients fail to respond, and medications are often needed. Currently available medications don't work very well and can have serious side effects. A new study tested a combination of two existing medications, dextromethorphan hydrobromide and quinidine sulfate, to see if this would help control agitation in patients with Alzheimer's dementia.

      Researchers from the Cleveland Clinic recruited 220 patients with Alzheimer's dementia and agitation. During a preliminary 10 week trial, participants were randomly assigned to receive either the dextromethorphan- quinidine combination or a placebo.

      Results showed that patients receiving the combination medication demonstrated fewer episodes of agitation compared to patients who received the placebo. When agitation did occur, it tended to be less severe. Researchers also found that not only is the combined drug effective, but safe.

      [Watch more videos of The JAMA Report]

      JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and The JAMA Network® journals.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Prova Education…
    but how about a more personalized experience?

    Register for free